ST Elevation Myocardial Infarction Clinical Trial
Official title:
Ticagrelor Administered as Standard Tablet or orodispersiblE foRmulation
Randomized clinical study evaluating superiority in platelet inhibition after administration of Ticagrelor 180 mg loading dose as an orodispersible formulation versus traditional coated tablets in patients admitted for ST elevation myocardial infarction or very high-risk non-ST elevation myocardial infarction.
Primary percutaneous coronary intervention (PPCI) is the preferred reperfusion strategy for patients with acute ST-segment elevation myocardial infarction (STEMI). Additional antithrombotic therapy prior or during intervention plays an important role in the short- and long-term outcomes after PPCI. Oral antiplatelet therapy including a platelet P2Y12 receptor inhibitors is a cornerstone of antithrombotic treatment in patients with acute coronary syndromes. Prasugrel and Ticagrelor have been shown to be superior to Clopidogrel in patients with STEMI in reduction of ischemic complication without any increase in the bleeding risk and with a significant reduction in the stent thrombosis rate. Nevertheless, in STEMI patients, pharmacodynamic studies showed prasugrel and ticagrelor oral loading dose (LD) provided a suboptimal platelet inhibition in the first hours after LD, and at least 4 hours are required to achieve and effective platelet aggregation inhibition in the majority of patients, in part due to slowed gut motility caused by morphine use. Orodispersible tablet (ODT) is a different tablet formulation that disperses upon contact with the moist mucosal surfaces of the oral cavity and quickly release its components before swallowing; thus local drug dissolution and absorption as well as onset of clinical effect can be obtained conveniently easily and quickly by bypassing gastrointestinal tract. Recently, Ticagrelor 90 mg ODT has become available and bioequivalence studies on healthy volunteers documented its effectiveness with consequent approval by European Medicine Agency of this formulation which is currently available on the market. Thus, the aim of the present study is to evaluate the superiority in platelet inhibition with 180 mg Ticagrelor loading dose (LD) administered as ODTs as compared with standard formulation, among patients with STEMI or very high-risk NSTEMI undergoing immediate PCI. Primary objective consists in evaluating platelet reactivity 1 hour after Ticagrelor loading dose by VerifyNow test. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05601999 -
Study of Efficacy and Safety of GNR-060 vs Metalyse in Patients With ST Elevation Myocardial Infarction
|
Phase 3 | |
Recruiting |
NCT06147986 -
Evaluate the Efficacy and Safety of Allogeneic Umbilical Cord Mesenchymal Stem Cells as an Add-On Treatment for Acute ST-elevation Myocardial Infarction (STEMI) Patients
|
Phase 2 | |
Not yet recruiting |
NCT05881382 -
Dutogliptin in Co-administration With Filgrastim in Early Recovery Post-myocardial Infarction
|
Phase 3 | |
Enrolling by invitation |
NCT02615015 -
SNPs in the DNase 1 Gene Impair Its Activity and Are Increased in a STE-ACS Patient Cohort Compared to Healthy Controls
|
N/A | |
Recruiting |
NCT05812963 -
IVUS Versus FFR for Non-infarct Related Artery Lesions in Patients With Multivessel Disease and Acute STEMI
|
N/A | |
Recruiting |
NCT05554588 -
Intrathrombus Thrombolysis Versus Aspiration Thrombectomy During Primary PCI
|
N/A | |
Recruiting |
NCT05450757 -
Shanghai ST-segment Elevation Myocardial Infarction Cohort
|
||
Active, not recruiting |
NCT03278509 -
Evaluation of Decreased Usage of Betablockers After Myocardial Infarction in the SWEDEHEART Registry (REDUCE-SWEDEHEART)
|
Phase 4 | |
Not yet recruiting |
NCT03266328 -
Procedure and In-hospital Outcome of Patients Under 40 Years Old Undergoing Primary Percutaneous Coronary Intervention for Acute ST Elevated Myocardial Infarction in Assiut University
|
N/A | |
Not yet recruiting |
NCT03263468 -
Revascularization StrategIes for ST Elevation Myocardial Infarction Trial
|
N/A | |
Completed |
NCT03156699 -
The Incidence, Effect and Persistence of Fragmented-QRS, in Patients Presenting With ST-Elevation Myocardial Infarction
|
||
Enrolling by invitation |
NCT04970238 -
Effect of Levosimendan on Left Ventricular Systolic Function and Heart Failure After PCI in Patients With Acute Anterior Myocardial Infarction
|
Phase 4 | |
Recruiting |
NCT02557217 -
NP202 for Treatment of Post -STEMI Left Ventricular Systolic Dysfunction
|
Phase 2 | |
Recruiting |
NCT02224534 -
Ticagrelor Versus Clopidogrel in Left Ventricular Remodeling After ST-segment Elevation Myocardial Infarction
|
Phase 4 | |
Completed |
NCT01136187 -
Trial Comparing Radial and Femoral Approach in Primary Percutaneous Coronary Intervention (PCI)
|
N/A | |
Not yet recruiting |
NCT04068116 -
Impact of Ischemic Post-conditioning
|
N/A | |
Not yet recruiting |
NCT04063345 -
Long-term Clinical Outcomes of intraVascular Ultrasound-guided vs Angiography-guided Primary pErcutaneous Intervention in Patients With Acute ST Segment Elevated Myocardial Infarction
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT03646357 -
BEtablocker Treatment After Acute Myocardial Infarction in Patients Without Reduced Left Ventricular Systolic Function
|
Phase 4 | |
Completed |
NCT03984071 -
The Predictive Value of eGFR for Adverse Cardiovascular Events in Patients With STEMI
|
||
Completed |
NCT03740776 -
The Eosinophils Percentage Predicts In-hospital Major Adverse Cardiac Events in STEMI Patients After PCI
|